Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-Lung-536: telisotuzumab adizutecan plus PD-1 inhibitor in untreated advanced non-squamous NSCLC without actionable genomic alterations
CTR20252837Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of telisotuzumab adizutecan in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc.. Started May 2026; status: active.
02
Drugs
telisotuzumab adizutecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252837.